Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05913388 · ClinicalTrials.gov registry record · Phase 2
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
A Phase 2 study of Head and Neck Squamous Cell Carcinoma and Metastatic Melanoma, sponsored by Providence Health & Services.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT05913388 is a Phase 2 study of Head and Neck Squamous Cell Carcinoma and Metastatic Melanoma that is actively recruiting participants, run by Providence Health & Services. The registered enrollment target is 92 participants, below the 116-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05913388, a Phase 2 study of Head and Neck Squamous Cell Carcinoma and Metastatic Melanoma, is actively recruiting participants, sponsored by Providence Health & Services.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the objective response of GB1211 and pembrolizumab versus pembrolizumab and placebo in patients with advance metastatic melanoma or head and neck squamous cell carcinoma.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
- DRUG GB1211
Study Locations (1)
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2024-02-29 |
| Est. Completion | 2030-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05913388
The ClinicalTrials.gov registry entry for NCT05913388 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (21% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05913388 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT05913388 about?
NCT05913388 is a clinical study titled "GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma". The purpose of this study is to determine the objective response of GB1211 and pembrolizumab versus pembrolizumab and placebo in patients with advance metastatic melanoma or head and neck squamous cell carcinoma.
What is the current status of trial NCT05913388?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2024-02-29. Estimated completion is 2030-02.
What conditions does trial NCT05913388 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Melanoma.
What interventions are being tested in trial NCT05913388?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), GB1211 (DRUG).
Who is sponsoring clinical trial NCT05913388?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05913388 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.